Affiliation:
1. P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
2. P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation;
I. M. Sechenov First Moscow State Medical University (Sechenov University);
Peoples' Friendship University of Russia
3. Сentral Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
Abstract
Purpose of the study. Evaluation of the diagnostic value of vacuum-assisted biopsy (VAB) based on pathomorphological studies in patients with breast cancer (BC) who have achieved a complete clinical response (cCR) after neoadjuvant polychemotherapy (NACT).Patients and methods. In the study, conducted from 2021 to 2023 at the P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Radiology Center of the Ministry of Health of Russia, 35 patients with BC cT1–3N0–3M0 of various molecular-biological types who were diagnosed with cCR after NACT were included. All patients underwent VAB (needle size 7–10 G) of the breast followed by histological examination, after which surgical treatment was performed. Subsequently, histological conclusions of VAB and surgical materials were compared with each other for the presence and degree of pathomorphological response.Results. According to the pathomorphological conclusion when conducting VAB, the following results were obtained: 1 – true positive, 29 – true negative, 3 – false negative, and 0 – false positive. No statistically significant results of the association between complete pathomorphological response and the molecular-biological type of breast cancer were obtained (p > 0.05), however, there is a tendency towards the greatest number of complete pathomorphological responses in Her2-neu-positive (luminal – 100 %, non-luminal – 90.9 %) and triple-negative (87.50 %) types of breast cancer. The overall sensitivity of the method was 25.0 % (CI 6.8–60.2 %); specificity – 100 % (CI 88.1–100 %); false-negative result (presence of tumor cells in the surgical material and a negative result of VAB) – 9.1 % (CI 3.4–20.2 %); false-positive result (absence of tumor cells in the surgical material and a positive result of VAB) – 0 % (CI 0–10.6 %). The overall diagnostic accuracy of the method was 90.9 % (CI 79.8–96.6 %).Conclusion. The results of the conducted research allow for the consideration of excluding surgical treatment when a complete pathomorphological response is obtained by VAB. However, further research is required with the inclusion of a larger number of patients.
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference18 articles.
1. Kaprin AD, Starinskii VV, Shakhzadova AO. state of oncological care to the population of Russia in 2021. Мoscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, 2022, 239 p. Available at: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onko- logicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf. Accessed: 22.11.2023.
2. Bennett IC, Saboo A. The Evolving Role of Vacuum Assisted Biopsy of the Breast: A Progression from Fine-Needle Aspiration Biopsy. World J Surg. 2019 Apr;43(4):1054–1061. https://doi.org/10.1007/s00268-018-04892-x
3. Bennett I, de Viana D, Law M, Saboo A. Surgeon-Performed Vacuum-Assisted Biopsy of the Breast: Results from a Multicentre Australian Study. World J Surg. 2020 Mar;44(3):819–824. https://doi.org/10.1007/s00268-019-05266-7
4. Pistolese CA, Castrignanò A, Ricci F, Meucci R, Croce G, Mondillo M, et al. Ultrasound-Guided Vacuum-Assisted Biopsy in Small Breast: A Cost-Saving Solution. Clin Breast Cancer. 2019 Apr;19(2):e352–357. https://doi.org/10.1016/j.clbc.2018.12.002
5. Hennigs A, Riedel F, Marmé F, Sinn P, Lindel K, Gondos A, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat. 2016 Dec;160(3):491–499. https://doi.org/10.1007/s10549-016-4016-4